Attention Deficit Hyperactivity Disorder in Adulthood

被引:0
作者
Philipsen, A. [1 ]
Hesslinger, B. [1 ]
van Elst, L. T. [1 ]
机构
[1] Univ Freiburg Klinikum, Abt Psychiat & Psychotherapie, D-79104 Freiburg, Germany
来源
DEUTSCHES ARZTEBLATT INTERNATIONAL | 2009年 / 105卷 / 17期
关键词
ADHD; adulthood; diagnosis; treatment; methylphenidate; DEFICIT/HYPERACTIVITY DISORDER; METHYLPHENIDATE; PSYCHOTHERAPY; EFFICACY; THERAPY; RISK; ADHD;
D O I
10.3238/arztebl.2008.0311
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Until the late nineties, attention deficit and hyperactivity disorder (ADHD) was often regarded in Germany as a disorder that fades away in late adolescence. However, it has recently become clear from numerous studies that core symptoms of ADHD persist into adulthood in a substantial subgroup of patients. Methods: Selective review of relevant literature in Medline, up to September 2007. Results: The prevalence of ADHD in adulthood is estimated at about 2%. Core symptoms include attention deficit in the presence of understimulation, chronic restlessness, impulsivity, disorganized behaviour, and disorders of affect regulation. The extent of psychosocial impairment depends on symptom severity, psychiatric comorbidity (such as addiction or depression), and psychosocial support. As in childhood, ADHD in adulthood is a clinical diagnosis. Genetic factors probably play a key role in primary ADHD. Treatment should include psychotherapy and medical treatment. Discussion: ADHD in adulthood is commoner than for example bipolar disorder or schizophrenia. It may be regarded as a risk factor for the development of other psychiatric conditions. Highly effective treatment is possible not only in childhood but also in adulthood. The problem of off-label use of psychotrophic medication in adults limits treatment in adult ADHD. Dtsch Arztebl Int 2008; 105(17): 311-7 DOI: 10.3238/arztebl.2008.0311
引用
收藏
页码:311 / U9
页数:8
相关论文
共 29 条
[1]  
*ADHS, 2007, STELL HER VORST BUND
[2]   Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetine [J].
Adler, Lenard A. ;
Sutton, Virginia K. ;
Moore, Rodney J. ;
Dietrich, Anthony P. ;
Reimherr, Frederick W. ;
Sangal, R. Bart ;
Saylor, Keith E. ;
Secnik, Kristina ;
Kelsey, Douglas K. ;
Allen, Albert J. .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2006, 26 (06) :648-652
[3]  
[Anonymous], HOMBURGER ADHS SKALE
[4]   Attention-deficit/hyperactivity disorder: A selective overview [J].
Biederman, J .
BIOLOGICAL PSYCHIATRY, 2005, 57 (11) :1215-1220
[5]  
BIEDERMAN J, 1995, ARCH GEN PSYCHIAT, V52, P464
[6]   Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder [J].
Biederman, Joseph ;
Mick, Eric O. ;
Surman, Craig ;
Doyle, Robert ;
Hammerness, Paul ;
Michel, Evan ;
Martin, Jessica ;
Spencer, Thomas J. .
BMC PSYCHIATRY, 2007, 7 (1)
[7]  
BIEDERMANN J, 2002, PEDIATRICS, V6, P1
[8]   Functional neuroimaging of attention-deficit/hyperactivity disorder: A review and suggested future directions [J].
Bush, G ;
Valera, EM ;
Seidman, LJ .
BIOLOGICAL PSYCHIATRY, 2005, 57 (11) :1273-1284
[9]   Environmental risk factors for attention-deficit hyperactivity disorder [J].
Das Banerjee, Tania ;
Middleton, Frank ;
Faraone, Stephen V. .
ACTA PAEDIATRICA, 2007, 96 (09) :1269-1274
[10]  
EBERT D, 2003, ADHS ERWACHSENENALTE, P939